Royal Bank Of Canada Affimed N.V. Transaction History

Royal Bank Of Canada

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.32 - $0.62 $1,726 - $3,344	-5,394 Reduced 12.37%	38,212 $23,000
Q3 2023 Nov 14, 2023	SELL	$0.46 - $0.65 $1,243 - $1,756	-2,703 Reduced 5.84%	43,606 $20,000
Q2 2023 Aug 14, 2023	SELL	$0.57 - $1.08 $11,995 - $22,728	-21,045 Reduced 31.25%	46,309 $27,000
Q1 2023 May 15, 2023	SELL	$0.66 - $1.29 $5,698 - $11,137	-8,634 Reduced 11.36%	67,354 $50,000
Q4 2022 Feb 14, 2023	BUY	$1.1 - $2.45 $7,111 - $15,839	6,465 Added 9.3%	75,988 $94,000
Q3 2022 Nov 14, 2022	BUY	$1.96 - $3.32 $26,848 - $45,477	13,698 Added 24.54%	69,523 $143,000
Q2 2022 Aug 15, 2022	SELL	$2.27 - $4.86 $15,508 - $33,203	-6,832 Reduced 10.9%	55,825 $154,000
Q1 2022 May 16, 2022	BUY	$3.69 - $5.65 $9,955 - $15,243	2,698 Added 4.5%	62,657 $274,000
Q4 2021 Feb 14, 2022	BUY	$5.37 - $7.07 $20,373 - $26,823	3,794 Added 6.76%	59,959 $331,000
Q3 2021 Nov 15, 2021	BUY	$5.54 - $7.51 $21,655 - $29,356	3,909 Added 7.48%	56,165 $347,000
Q2 2021 Aug 16, 2021	BUY	$7.78 - $11.4 $406,551 - $595,718	52,256 New	52,256 $445,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $520M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.